Carlo Castillo, DO
Nephrology · Huntsville, ALNPI 1518176031
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,661, 2.2 times the $750 reported in 2019.
Across 373 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$816
- Vifor Pharma, Inc.$759
- Bayer$681
- OPKO Pharmaceuticals, LLC$651
- Novartis$561
- Calliditas Therapeutics US Inc.$509
- plus $3K from 24 others
Across 133 payments — averaging $3413.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$146K
- CSL Behring$97K
- Boehringer Ingelheim International GmbH$83K
- Boehringer Ingelheim Pharma GmbH & Co.kg$80K
- Novartis$48K
What the payments were for
- Food & beverage$7,22199%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 28 | $816 |
| Vifor Pharma, Inc. | 43 | $759 |
| Bayer | 23 | $681 |
| OPKO Pharmaceuticals, LLC | 72 | $651 |
| Novartis | 22 | $561 |
| Calliditas Therapeutics US Inc. | 20 | $509 |
| AstraZeneca(2 entities) | 32 | $507 |
| Otsuka America Pharmaceutical, Inc. | 27 | $464 |
| GSK | 16 | $326 |
| Akebia Therapeutics Inc | 9 | $300 |
| Boehringer Ingelheim | 13 | $287 |
| Aurinia Pharma U.S., Inc. | 11 | $270 |
| Travere Therapeutics, Inc. | 15 | $227 |
| Ardelyx, Inc. | 5 | $206 |
| Novo Nordisk | 6 | $144 |
| Lilly USA, LLC | 5 | $101 |
| Mallinckrodt Hospital Products Inc. | 3 | $69 |
| Ultragenyx Pharmaceutical Inc. | 3 | $60 |
| Medtronic | 2 | $60 |
| Apellis Pharmaceuticals, Inc. | 3 | $55 |
| Fresenius USA Marketing, Inc. | 3 | $45 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| AMAG Pharmaceuticals, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Parsabiv$355
- Kerendia$125
- TARPEYO$122
- XPHOZAH 30 MG$118
How this compares
$7,319 in reported general payments places this provider in the 80th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 20 | $46,395 |
| VeltassaPatiromer Calcium Sorbitex | 39 | $39,775 |
| FarxigaDapagliflozin Propanediol | 13 | $13,990 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $10,795 |
| Sevelamer Carbonate | 64 | $10,262 |
| Hydralazine Hcl | 86 | $1,514 |
| Nifedipine ErNifedipine | 65 | $1,489 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,430 |
| Calcitriol | 30 | $1,202 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 52 | $836 |
| Telmisartan | 27 | $658 |
| Torsemide | 41 | $564 |
| Losartan Potassium | 40 | $456 |
| Carvedilol | 55 | $405 |
| Potassium Chloride | 22 | $390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $45 | $46,39520 claims |
| AstraZenecaFarxiga, Lokelma | $507 | $24,78531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 nephrology providers in Alabama.
Other nephrology in Huntsville
- Michael QuadriniHuntsville$323K
- James SmelserHuntsville$20K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Roger CoomerHuntsville$6K
- David BainsHuntsville$5K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.